8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Apr 15, 2026·SEC
Catheter Precision, Inc.(VTAK)Earnings, Financials & Key Ratios
VTAK•AMEX
$1.21
Price updated Jun 25, 2026
AboutCatheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.Show more
- Revenue$819K+95.0%
- EBITDA-$10M-10.2%
- Net Income-$17M-3.2%
- EPS (Diluted)-15.90-138.0%
- Gross Margin92.31%+2.6%
- EBITDA Margin-1229.06%+43.5%
- Operating Margin-1487.3%+44.4%
- Net Margin-2098.05%+47.1%
- ROE-186.69%-84.8%
VTAK Price & Volume
Catheter Precision, Inc. (VTAK) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Clinical Commercialization Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
"Catheter Precision faces a critical liquidity inflection point as its high-touch electrophysiology business model struggles to scale against a massive fixed-cost burden. While the company maintains gross margins exceeding 90%, the inability to convert this structural efficiency into positive operating income suggests significant execution risk. Investors should monitor the company's ability to secure non-dilutive capital, as the current cash position of $441,000 against $12.0 million in debt creates an unsustainable financial profile."
Verdict Logic
the company's liquidity position is critical, with a cash balance of only $441,000 as of 2026Q1, which appears insufficient to support ongoing operations without immediate and potentially dilutive external financing.
VTAK Growth Metrics
Catheter Precision, Inc. (VTAK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years25.89%
3 Years288.2%
TTM130.35%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.91%
Return on Capital
10 Years-162%
5 Years-176.17%
3 Years-174.26%
Last Year-64.73%
VTAK Recent Earnings
Catheter Precision, Inc. (VTAK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$1.39+93.3%
$20.90
Rev
$432,000-73.0%
$2M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$1.53+107.3%
$20.90
Rev
$238,000-86.0%
$2M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.70+93.6%
$26.60
Rev
$226,000-81.2%
$1M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$7.22+78.9%
$34.20
Rev
$212,000-64.7%
$600,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $1.39vs $20.90+93.3% | $432,000vs $2M-73.0% |
| Q2 2026 | Mar 31, 2026 | $1.53vs $20.90+107.3% | $238,000vs $2M-86.0% |
| Q4 2025 | Nov 13, 2025 | $1.70vs $26.60+93.6% | $226,000vs $1M-81.2% |
| Q3 2025 | Aug 11, 2025 | $7.22vs $34.20+78.9% | $212,000vs $600,000-64.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Catheter Precision, Inc. (VTAK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.21 | $2.65B | -0.08 | 95% | -2098.05% | -186.69% | — | |
| $28.13 | $1.42B | -117.21 | 14.88% | -0.83% | -0.95% | — | |
| $0.64 | $22.04M | -1.03 | — | — | -1034.04% | — | |
| $115.99 | $3.81B | -83.45 | 26.24% | -3.53% | -20.6% | — | |
| $40.05 | $331.62M | 46.57 | 16.97% | 14.08% | 22.14% | — | |
| $44.20 | $65.7B | 22.78 | 19.87% | 17.23% | 14.67% | — |
Compare VTAK vs Peers
Catheter Precision, Inc. (VTAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTAK SEC Filings & Documents
Catheter Precision, Inc. (VTAK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VTAK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VTAK Frequently Asked Questions
Catheter Precision, Inc. (VTAK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Catheter Precision, Inc.'s revenue?
Catheter Precision, Inc. (VTAK) reported $1.1M in revenue for fiscal year 2025. This represents a 81% decrease from $6.0M in 2016.
How fast is Catheter Precision, Inc. growing?
Catheter Precision, Inc. (VTAK) grew revenue by 95.0% over the past year. This is strong growth.
Is VTAK profitable?
Catheter Precision, Inc. (VTAK) reported a net loss of $14.8M for fiscal year 2025.
Dividend & Returns
What is VTAK's return on equity?
Catheter Precision, Inc. (VTAK) has a return on equity (ROE) of -186.7%. Negative ROE indicates the company is unprofitable.
What is Catheter Precision, Inc.'s free cash flow?
Catheter Precision, Inc. (VTAK) had negative free cash flow of $8.8M in fiscal year 2025, likely due to heavy capital investments.